Table 3.
Analysis of potential variables associated with LVRR.
| Univariate Analysis | Multivariable Analysis, NTProBNP Included | Multivariable Analysis, NTProBNP Not Included | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | p Value | OR | 95% CI | p Value | OR | 95% CI | p Value | |
| Age (years) | 0.98 | 0.96–0.99 | <0.001 | 0.98 | 0.96–0.99 | 0.045 | 0.98 | 0.97–0.99 | 0.038 |
| Male sex | 1.10 | 0.75–1.6 | 0.60 | – | – | – | – | – | – |
| Hypertension | 1.41 | 1–2.00 | 0.05 | – | – | – | 1.59 | 1.07–2.37 | 0.022 |
| Diabetes Mellitus | 0.86 | 0.60–1.25 | 0.44 | – | – | – | – | – | – |
| Dyslipemia | 0.87 | 0.61–1.23 | 0.42 | – | – | – | – | – | – |
| COPD | 1.32 | 0.84–2.10 | 0.22 | – | – | – | – | – | – |
| SBP (mmHg) | 1.01 | 1.00–1.01 | 0.28 | – | – | – | – | – | – |
| Heart rate (bpm) | 1.00 | 0.98–1.01 | 0.26 | – | – | – | – | – | – |
| Haemoglobin (g/L) | 1.05 | 0.95–1.15 | 0.36 | – | – | – | – | – | – |
| eGFR(mL/min) | 1.00 | 0.99–1.01 | 0.098 | 0.99 | 0.98–0.99 | 0.002 | – | – | – |
| logNT-proBNP (ng/L) | 0.78 | 0.67–0.92 | 0.002 | 0.66 | 0.53–0.81 | <0.001 | – | – | – |
| logHF duration (months) | 0.72 | 0.65–0.80 | <0.001 | 0.78 | 0.68–0.90 | 0.001 | 0.73 | 0.66–0.82 | <0.001 |
| III-IV NYHA class | 0.62 | 0.41–0.93 | 0.02 | – | – | – | – | – | – |
| Initial iLVEDD (mm) | 0.95 | 0.92–0.99 | 0.04 | 0.95 | 0.90–0.99 | 0.046 | – | – | – |
| Initial LVEF (%) | 0.95 | 0.93–0.97 | <0.001 | 0.90 | 0.86–0.94 | <0.001 | 0.93 | 0.90–0.95 | <0.001 |
| Sinus rhythm | 1.45 | 0.98–2.1 | 0.64 | – | – | – | – | – | – |
| Absence of LBBB | 2.3 | 1.47–3.60 | <0.001 | 2.94 | 1.61–5.36 | <0.001 | 2.42 | 1.47–3.97 | 0.001 |
| QRS complex (ms) | 0.99 | 0.98–0.99 | <0.001 | – | – | – | – | – | – |
| ICD | 0.73 | 0.42–1.26 | 0.26 | – | – | – | – | – | – |
| CRT | 0.84 | 0.46–1.54 | 0.60 | – | – | – | – | – | – |
| ACEI/ARB | 1.00 | 0.45–2.60 | 0.90 | – | – | – | – | – | – |
| Betablocker | 1.71 | 0.90–3.50 | 0.09 | – | – | – | – | – | – |
| Aldosterone antagonist | 0.88 | 0.60–1.26 | 0.50 | – | – | – | – | – | – |
| Diuretics | 1.4 | 0.78–2.66 | 0.25 | – | – | – | – | – | – |
Data presented as odds ratios and 95% confidence intervals from the logistic regression models. Abbreviations: ACEI/ARB: angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists; COPD = chronic obstructive pulmonary disease; CRT = cardiac resynchronization therapy; eGFR = estimated glomerular filtration rate; HF = heart failure; ICD = implantable cardioverter-defibrillator; iLVEDD = indexed left ventricular end-diastolic diameter; LBBB = left bundle branch block; LVEF = left ventricle ejection fraction; LVRR = left ventricular reverse remodelling; NTproBNP = N-terminal prohormone of brain natriuretic peptide; NYHA = New York Heart Association; SBP = systolic blood pressure.